The concept of the polypill in the prevention of cardiovascular disease

Annals of Global Health

Volumn 80, Issue 1, 2014, Pages 24-34

  Wiley, Brandon ^a   Fuster, Valentin ^a,b,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Marie Josee and Henry R Kravis Center for Cardiovascular Health   (United States)

^c CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

Author keywords

Cardiovascular disease; Polypill; Prevention; Public health

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOLIC ACID; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; LOSARTAN; MEVINOLIN; POLYCAP; RAMIPRIL; SIMVASTATIN; UNCLASSIFIED DRUG; ANTITHROMBOCYTIC AGENT; DRUG COMBINATION;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; COST EFFECTIVENESS ANALYSIS; HEART INFARCTION; HUMAN; MEDICALIZATION; MEDICATION COMPLIANCE; MORBIDITY; NON COMMUNICABLE DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); POLYPHARMACY; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SECONDARY PREVENTION; CARDIOVASCULAR DISEASES; DRUG COMBINATION;

ANTIHYPERTENSIVE AGENTS; ASPIRIN; CARDIOVASCULAR DISEASES; DRUG COMBINATIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PLATELET AGGREGATION INHIBITORS; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SECONDARY PREVENTION;

EID: 84904504321     PISSN: 22149996     EISSN: 22149996     Source Type: Journal    
DOI: 10.1016/j.aogh.2013.12.008     Document Type: Review

References (49)

1. Resolution 65/238. United Nations General Assembly, 2010. Available at: http://www.un.org/en/ga/president/65/issues/A-RES-65-238. pdf. Accessed November 5, 2012.
2. Prevention and control of non-communicable diseases, Report of Secretary-General, United Nations General Assembly, Sixty-sixth Session, 2011. Available at: http://www.who.int/nmh/events/un- ncd-summit2011/en/. Accessed November 5, 2012.
3. World Health Statistics. 2011. Cardiovascular diseases (CVDs) fact sheet. Available at: http://www.who.int/mediacentre/factsheets/fs317/en/. Accessed November 12, 2012.
4. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113: 791-8.
5. Mendis S, Puska P, Norrving B. Global Atlas on Cardiovascular Disease Prevention and Control. Geneva, Switzerland: World Health Organization; 2004.
6. Roger V, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics - 2011 update: a report from the American Heart Association. Circulation. 2011;123:e18-209.
7. European Health Heart Charter. Available at: http://www.heartcharter. eu/. Accessed November 12, 2012.
8. Daar AS, Singer PA, Persad DL, et al. Grand challenges in chronic non-communicable disease. Nature. 2007;450: 494-6.
9. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case control study. Lancet. 2004;364: 937-52.
10. World Health Organization. Global status report on noncommunicable diseases. Geneva, Switzerland: World Health Organization; 2010.
11. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326: 1419-24.
12. Wald NJ, Wald DS. Polypill concept. Postgrad Med J. 2010;85: 1015.
13. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326: 1423-9.
14. Carey KM, Comee MR, Donovan JL, Kanaan AO. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke. Ann Pharmacother. 2012;46: 688-95.
15. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomized trials. BMJ. 2003;346: 1427-34.
16. Wald DS, Law MR,Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325: 1202-8.
17. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354: 1567-77.
18. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373: 1849-60.
19. Greving JP, Buskens E, Koffijberg H, Algra A. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk. Circulation. 2008;117: 2875-83.
20. Taylor F, Ward K, Moore THM, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews. 2011;1:CD004816.
21. Verdecchi P, Reboldi G, Angeli F, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension. 2005;46: 386-92.
22. Sanz G, et al. The Fixed-dose Combination Drug for Secondary Cardiovascular Prevention project: Improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives. Am Heart J. 2011;162: 811-817.e1.
23. Guglietta A, Guerrero M. Issues to consider in the pharmaceutical development of a cardiovascular polypill. Nat Clin Pract Cardiovasc Med. 2009;6: 112-9.
24. Patel A, Shah T, Shah G, et al. Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (Polycap). Am J Cardiovasc Drugs. 2010;10: 95-103.
25. The Indian Polycap Study. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. Lancet. 2009;373: 1341-51.
26. Malekzadeh A. pilot double-blind randomized placebo-controlled trial of the effects of fixed-dose combination therapy ('polypill') on cardiovascular risk factors. Int J Clin Pract. 2010;64: 1220-7.
27. Group PC, et al. An international randomised placebo-controlled trial of four-component combination pill ("polypill") in people with raised cardiovascular risk. PLoS One. 2011;6:e19857.
28. Wald DS, Morris JK, Wald NJ. Randomized polypill crossover trial in people aged 50 and over. PLoS One. 2012;7:e41297.
29. POLYIRAN in Primary and Secondary Prevention of Cardiovascular Disease in Middleaged and Elderly Iranians. Available at: ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT01271985. Accessed November 15, 2012.
30. The International Polycap Study 3 (TIPS-3). Available at: ClinicalTrials. gov http://clinicaltrials.gov/ct2/show/study/NCT01646437 Accessed November 15, 2012.
31. Gaziano TA, Opie LH, Weinstein MC. Cardiovascular disease prevention with a multidrug regimen in the developing world: a costeffectiveness analysis. Lancet. 2006;368: 679-86.
32. O'Riordan M. One pill to cure them all: single-drug polypharmacy in cardiovascular disease. Available at: http://theheart.org. Accessed November 15, 2012.
33. Verweij M. Medicalization as a moral problem for preventive medicine. Bioethics. 1999;13: 89-113.
34. Ford EA, Ajani UA, Croft JB, et al. Explaining the decline in coronary mortality in the United States between 1980 and 2000. N Engl J Med. 2007;356: 2388-98.
35. Lonn E, Bosch, Teo KK, Pais P, Xavier D, Yusuf S. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation. 2010;122: 2078-88.
36. Farkouh ME, Domanski M, Sleeper LA, et al. for the FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012;367: 2375-84.
37. Muntner P, Mann D, Wildman RP, Shimbo D, Fuster V, Woodward M. Projected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects. Am Heart J. 2011;161: 719-25.
38. Fuster V, Nahum J. Winer Lecture "Transitions from Cardiovascular Disease to Health (2012-2020): The Challenge of Identifying Subclinical Disease." Lecture presented at: New York Academy of Medicine. October 10, 2012. New York, New York.
39. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009;16: 121-37.
40. Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middleincome, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011;378: 1231-43.
41. Mendis S, Fukino K, Cameron A, et al. The availability and affordability of selected essential medicines for chronic diseases in six lowand middle-income countries. Bull World Health Organ. 2007;85: 279-88.
42. Sanz G, Fuster V. Polypill and global cardiovascular health strategies. Semin Thoracic Surgery. 2011;23: 24-9.
43. Lahoud R, Howe M, Krishnan SM, Zacharias S, Jackson EA. Effect of use of combination evidence-based medical therapy after acute coronary syndromes on long-term outcomes. Am J Cardiol. 2012;109: 159-64.
44. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288: 462-7.
45. Newby LK, LaPointe NMA, Chen AY, et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation. 2006;113: 203-12.
46. Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008;155: 772-9.
47. Thom SA. Use of a Multidrug Pill in Reducing Cardiovascular Events (UMPIRE). Paper presented at: AHA Scientific Sessions. November 5, 2012. Los Angeles, California.
48. SPACE Collaboration (Single Pill to Avert Cardiovascular Events). Available at: http://www.spacecollaboration.org Accessed November 15, 2012.
49. O'Riordan M. UMPIRE's ruling: Fixed-dose combo improves adherence, lowers cholesterol and BP. Available at: http://theheart.org Accessed November 15, 2012.